Latest academic and careers news

academic and careers

Trump’s politicization of US intelligence agencies could end in disaster

By webfeeds.brookings.edu
Published On :: Tue, 28 Apr 2020 20:59:15 +0000

academic and careers

The State of Drug Safety Surveillance in the U.S.: Much Improved, More to Come

By webfeeds.brookings.edu
Published On :: Fri, 08 Feb 2013 13:30:00 -0500

When a new drug is approved in the United States, it is virtually impossible to know all of the risks that a population may encounter when using that product. Even though the U.S. Food and Drug Administration (FDA) requires drug manufacturers to meet rigorous standards demonstrating the drug’s safety and effectiveness for its intended use, once approved, drugs can be used by many more patients than were studied in clinical trials. This may include patients with unique clinical conditions, differing health status, ethnicity, age, or other characteristics which were not well-represented before the drug’s approval. Further, the drugs themselves can be used in different ways and in different settings than were studied. Until recently, FDA did not have the necessary tools and data access to rapidly and consistently track the risks of serious side effects of regulated drugs after approval. Recognizing this challenge, FDA has developed a pilot system to make the best use of available electronic health data using a new data and research network capable of evaluating the safety of medical products in the U.S.

Authorized by the Food and Drug Administration Amendments Act (FDAAA) of 2007, this pilot is known as Mini-Sentinel, and is part of FDA’s larger Sentinel Initiative. Sentinel was envisioned as a national electronic system to track the safety of regulated medical products, through the use of existing health insurance claims and electronic clinical data that are generated as part of routine care. In the four years since its inception, Mini-Sentinel has made tremendous progress toward developing this system. Mini-Sentinel is comprised of insurance claims and clinical data from 18 participating data-partners, including some of the largest private health plans in the United States. In order to best protect patient privacy, the data from each partner is maintained behind each individual health plan fire-wall. This “distributed data” approach allows a single coordinating center to distribute FDA safety questions in the form of “queries,” to each of the participating data partners to be run against their own data. Aggregated summary results are then sent back to the coordinating center for final analysis. This process allows FDA to access data that can help in addressing safety questions in near real-time.

Through Mini-Sentinel, FDA has the capability to better understand the safety outcomes using electronic health care data of approximately 169 million covered lives. This accumulation of data represents the capture of 382 million person-years of observation time and billions of prescription dispensings.[1] Examples of the types of safety questions that have already been addressed by Mini-Sentinel include the following:

Safety concerns with drugs used to treat high blood pressure and the incidence of angioedema;
Safety concerns with a new diabetes treatment and the incidence of heart attacks; and
Impact of FDA regulatory actions (i.e. drug label changes) intended to mitigate serious risks of drugs.

The Mini-Sentinel pilot has demonstrated substantial progress and has proven to be a very useful tool for FDA, largely due to the strong partnerships developed between FDA, collaborating academic institutions, and private health plans. However, in order to ensure continued progress and long-term sustainability, it will be critical for progress to continue in several key areas.

First, continued methods development and data understanding will be necessary to ensure FDA has access to the most innovative tools. The field of pharmacoepidemiology and drug safety surveillance is still young and the continued development of better study designs and analytic tools to quantify risks of serious adverse events, while accounting for many confounding factors that are inherent on observational data, will be critical. Further, as health reforms impact that way health care is delivered and financed (e.g., development of accountable care organizations and increased use of bundled payments), the electronic health data will change. It will be important to focus efforts on understanding how these changes will impact data used for safety evaluations.

Second, it is clear that Sentinel’s contributions may extend well beyond FDA’s medical product assessments. The tools and infrastructure that have been developed by FDA over the last four years could be used as a platform to establish a national resource for a more evidence-based learning health care system. This system will enable a better understanding of not only the risks, but also benefits and best uses, of drugs in the post-market settings.

FDA has initiated steps to ensure the long-term sustainability and impact of Sentinel infrastructure and tools. Within the next few years, FDA has proposed that Sentinel be transitioned into three main components: the Sentinel Operations Center, the Nation Resource Data Infrastructure, and the Methodological Resource for Medical Product Surveillance using Electronic Healthcare Databases. FDA has indicated that while the Sentinel Operations Center will continue to serve as FDA’s portal to the distributed database, the Nation Resource Data Infrastructure could potentially be used by other groups to support broader evidence generation. Potential groups with interest in improving our understanding of the impact of medical products and who could benefit from this framework include the National Institutes of Health, the Regan-Udall Foundation, the Patient Centered Outcomes Research Institute, and other possible stakeholder groups, such as the private industry.

Collectively, these components will ensure that FDA continues to have the tools to engage in medical product surveillance, while ensuring the long-term sustainability of the system. In just four years, the Sentinel Initiative has laid the groundwork to transform how FDA, and the nation, benefits from electronic health care data. This network continues to foster a community of stakeholders committed the evidence generation, which will ultimately contribute to a learning health care system.

New Advances in Medical Records Reflects the Realities of the U.S. Healthcare System

For more information on these issues, including discussion by leaders from Sentinel stakeholders, please visit the Sentinel Initiative Public Workshop event page. There you will find archived video, presentations, and further reading.

[1] http://mini-sentinel.org/about_us/MSDD_At-a-Glance.aspx

Video

New Advances in Medical Records Reflects the Realities of the U.S. Healthcare System

Authors

Gregory W. Daniel
Heather Colvin
Paul Trompke

Trump’s politicization of US intelligence agencies could end in disaster

The State of Drug Safety Surveillance in the U.S.: Much Improved, More to Come

Video

Authors

What past oil crashes say about today’s slump

Stocks and the economy

Is there any ammo left for recession fighting?

Yawn, another OPEC meeting

Should the Fed’s discretion be constrained by rules?

Donald Trump’s fiscal package promises to promote expansion

Will President Trump derail the U.S. economy?

There’s no recession, but a market correction could cause one

The new oil market: Chaos or order?

Oil prices are tumbling. Volatility aside, expect them to stay low over the next 20 years.

فيروس كورونا المستجدّ سيُطيل الصراع في الشرق الأوسط

Iran’s corona-diplomacy

How Gulf states can lead the global COVID-19 response

كيف يمكن للدول الخليجية أن تقود الاستجابة العالمية لفيروس كورونا المستجدّ

GCC News Roundup: Saudi Arabia, UAE, Qatar, Kuwait implement new economic measures (April 1-30)

Webinar: Public health and COVID-19 in MENA: Impact, response and outlook

الصحّة العامة وفيروس كورونا المستجدّ في الشرق الأوسط وشمال أفريقيا: التداعيات والاستجابات والتوقّعات

Pandemic politics: Does the coronavirus pandemic signal China’s ascendency to global leadership?

السياسات بشأن الجائحة: هل تشير جائحة فيروس كورونا المستجدّ إلى صعود الصين إلى القيادة العالميّة؟

دبلوماسية الكورونا في إيران جهود إدارة روحاني الخاطئة من أجل رفع العقوبات

It’s George Wallace’s World Now

Too Much Democracy Is Bad for Democracy

Black Americans are not a monolithic group so stop treating us like one

The killing of Ahmaud Arbery highlights the danger of jogging while black

The CARES Act Risks Becoming a Caste Act. Here’s How We Change That.

Artificial Intelligence Won’t Save Us From Coronavirus

Why AI systems should disclose that they’re not human

New polling data show Trump faltering in key swing states—here’s why

In the Republican Party establishment, Trump finds tepid support

Ahmaud Arbery and the dangers of running while black

Record-setting White House staff turnover continues with news of Counsel’s departure

In search of a third chief of staff, Trump sets a record

Tracking turnover in the Trump administration

Kirstjen Nielsen, secretary of Homeland Security, out amidst national emergency

Who is in the president’s Cabinet?

With Acosta’s resignation, how is high turnover affecting the administration?

Crippling the capacity of the National Security Council

And then there were ten: With 85% turnover across President Trump’s A Team, who remains?

Webinar: How federal job vacancies hinder the government’s response to COVID-19

How instability and high turnover on the Trump staff hindered the response to COVID-19

How might COVID-19 affect the global economy?

Around-the-halls: What the coronavirus crisis means for key countries and sectors

How will the Chinese economy rebound from COVID-19?

How will COVID-19 reshape America’s logistics workforce?

The politics of Congress’s COVID-19 response

What drove oil prices through the floor this week?

China and the West competing over infrastructure in Southeast Asia

How to ensure Africa has the financial resources to address COVID-19

EXHIBIT: Voices for the Environment: A Century of Bay Area Activism, Nov. 14

Do Cash Transfers Save Lives?, Nov. 19

The Power of Black Excellence: HBCUs and the Fight for American Democracy, Nov. 19

EXHIBIT: Voices for the Environment: A Century of Bay Area Activism, Nov. 14

Karen's Witch by Martin, Ann M.

Holiday Pop-Up Shop, Dec. 15

Holiday Pop-Up Shop, Dec. 14

Holiday Pop-Up Shop, Dec. 13

Holiday Pop-Up Shop, Dec. 12

Holiday Pop-Up Shop, Dec. 11

Member Event: Holiday Pop-Up Shop Preview, Dec. 10

Michael D. McCann, MD, MBA, Celebrated for Excellence in Health Care and Education

24-0694

24-0785

24-0725R1

Subscribe To Our Newsletter